Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q4 2016 · 10-K
Revenue$151.66M$151.66M−5.1% vs Q4 2015 Net Income$37.39M$37.39M+12.1% vs Q4 2015 EPS Diluted$0.77$0.77+8.5% vs Q4 2015 Gross Profit$50,929,000−21.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived-$12,651,000N/M Free Cash Flowderived-$32,608,000N/M Margins · derivedGross margin33.6%−7.2 pt vs Q4 2015
Operating margin33.6%+2.3 pt vs Q4 2015
Net margin24.7%+3.8 pt vs Q4 2015
ended Dec 31, 2016 · filed Feb 28, 2017 · 59 d after period end